Test

An Australian researcher who is internationally recognised for her work on mapping the genetics of breast, ovarian and other cancers has just been awarded the prestigious 2022 GSK Award for Research Excellence. 

Professor Georgia Chenevix-Trench – who is currently a Distinguished Scientist at The QIMR Berghofer Medical Research Institute – has won the 2022 GSK ARE in recognition of her research investigating genetic predispositions to breast and ovarian cancer. Her research has elevated global understanding of why some people have a genetic risk to cancer and what determines it. Her work also has contributed to the development of better screening, possible prevention solutions and treatment options for patients. 

Professor Chenevix-Trench says that understanding the biology behind the genomes of cancer cells is key in improving patient outcomes.  

“I’ve had an interest in helping those affected by hereditary cancers my entire life,” says Professor Chenevix-Trench. “Over the last five years, my focus has been to understand how genetic variants act as a determining factor in developing breast cancer. Unless we know how these genomes operate in relation to cancerous cells, we won’t be able to translate the knowledge we have gained into tangible treatment options and preventative solutions for patients.”   

Breast cancer is the most common cancer affecting Australian women, with approximately 57 people being diagnosed every day in 2022.¹ Professor Chenevix-Trench's research has helped the scientific community gain a better understanding of those at risk of the disease.